TSVT | tickerfilter.com

Fundamental analysis

17%

Profitability 0%

Dept financing 16%

Liquidity 75%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.21%

1 Month

74.64%

3 Months

96.39%

6 Months

0.20%

1 Year

-13.14%

2 Year

-47.87%

Key data

Stock price

$4.89

P/E Ratio

0.00

DAY RANGE

$4.88 - $4.97

EPS

$0.10

52 WEEK RANGE

$2.29 - $5.52

52 WEEK CHANGE

-$6.50

MARKET CAP

151.670 M

YIELD

N/A

SHARES OUTSTANDING

51.498 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

2.77

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,866,396

AVERAGE 30 VOLUME

$2,848,560

Company detail

CEO: Nick Leschly
Region: US
Website: 2seventybio.com
Employees: 440
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

2seventy bio, Inc. focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT - 2seventy bio, Inc.